Cargando…

Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults

INTRODUCTION: In 2020, prior to COVID-19 vaccine rollout, the Brighton Collaboration created a priority list, endorsed by the World Health Organization, of potential adverse events relevant to COVID-19 vaccines. We adapted the Brighton Collaboration list to evaluate serious adverse events of special...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fraiman, Joseph, Erviti, Juan, Jones, Mark, Greenland, Sander, Whelan, Patrick, Kaplan, Robert M., Doshi, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428332/ https://www.ncbi.nlm.nih.gov/pubmed/36055877 http://dx.doi.org/10.1016/j.vaccine.2022.08.036

Ejemplares similares

Letter to the editor
por: Fraiman, Joseph, et al.
Publicado: (2023)

Safety of Delafloxacin: Focus on Adverse Events of Special Interest
por: Lodise, Thomas, et al.
Publicado: (2018)

Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong
por: Lai, Francisco Tsz Tsun, et al.
Publicado: (2022)

Serious adverse events associated with yellow fever vaccine
por: de Menezes Martins, Reinaldo, et al.
Publicado: (2015)

Influenza Vaccination of Pregnant Women and Serious Adverse Events in the Offspring
por: Donzelli, Alberto
Publicado: (2019)

Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study
por: Wong, Carlos King Ho, et al.
Publicado: (2022)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
por: Zhao, Bin, et al.
Publicado: (2018)

Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines
por: Pillsbury, Alexis, et al.
Publicado: (2023)

Factors related to the serious adverse events in patients visiting the emergency department after ChAdOx1 and mRNA COVID-19 vaccination
por: Jeong, Won Jung, et al.
Publicado: (2022)

Serious Neurological Adverse Events of Ceftriaxone
por: Lacroix, Clémence, et al.
Publicado: (2021)

Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019–2020
por: Moll, Keran, et al.
Publicado: (2023)

Inspiration to mRNA-based COVID-19 vaccination: Serious adverse case reports with hepatitis B vaccine in real-world
por: Lu, Jinmiao, et al.
Publicado: (2022)

COVID-19 mRNA Vaccines: The Molecular Basis of Some Adverse Events
por: Giannotta, Girolamo, et al.
Publicado: (2023)

Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study
por: Li, Xintong, et al.
Publicado: (2021)

Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study
por: Li, Xintong, et al.
Publicado: (2021)

Identification of serious, unpredictable adverse events with tocilizumab
Publicado: (2020)

Serious adverse event: late neurotropic disease associated with yellow fever vaccine
por: de Oliveira, Henrique Souza Barros, et al.
Publicado: (2020)

Yellow fever vaccine and risk of developing serious adverse events: a systematic review
por: Porudominsky, Ruben, et al.
Publicado: (2018)

Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study
por: Willame, C, et al.
Publicado: (2023)

Analysis of serious adverse event: Writing a narrative
por: Nambiar, Indu
Publicado: (2018)

Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis
por: Vinson, D., et al.
Publicado: (2020)

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
por: Zhao, Bin, et al.
Publicado: (2019)

Safety and Adverse Events Related to COVID-19 mRNA Vaccines; a Systematic Review
por: SeyedAlinaghi, SeyedAhmad, et al.
Publicado: (2022)

Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience
por: Bloise, Silvia, et al.
Publicado: (2022)

Algorithm for the support of non-related (serious) adverse events in an Ebola vaccine trial in the Democratic Republic of the Congo
por: Lemey, Gwen, et al.
Publicado: (2021)

LB766 Prevalence and adverse events of special interest among COVID19-vaccinated patients with chronic inflammatory skin diseases: An early look
por: Raiker, R., et al.
Publicado: (2021)

Vaccine trials with no serious adverse reactions – estimation of upper 95% confidence intervals for likelihood of such events
por: Grech, Victor, et al.
Publicado: (2022)

Corticosteroids Contribute to Serious Adverse Events Following Live Attenuated Varicella Vaccination and Live Attenuated Zoster Vaccination
por: Price, Nathan B., et al.
Publicado: (2021)

Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis
por: Awadzi, Kwablah
Publicado: (2003)

Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers
por: Wi, Yu-Mi, et al.
Publicado: (2021)

COVID-19 mRNA Vaccination in Lactation: Assessment of adverse events and vaccine related antibodies in mother-infant dyads
por: Golan, Yarden, et al.
Publicado: (2021)

COVID-19 mRNA Vaccination in Lactation: Assessment of Adverse Events and Vaccine Related Antibodies in Mother-Infant Dyads
por: Golan, Yarden, et al.
Publicado: (2021)

Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance
por: Nasreen, Sharifa, et al.
Publicado: (2022)

Short term adverse event profile of COVID-19 mRNA vaccines in children aged 5–15 years in Australia
por: Wood, Nicholas, et al.
Publicado: (2023)

Ad26.COV2.S COVID-19 vaccine: TTS a rare, but serious adverse event
Publicado: (2022)

First vaccination after birth: serious adverse events of Bacillus Calmette-Guérin (BCG) in real-world
por: Lu, Jinmiao, et al.
Publicado: (2022)

A comparative analysis on serious adverse events reported for COVID-19 vaccines in adolescents and young adults
por: Cappelletti-Montano, Beniamino, et al.
Publicado: (2023)

Adverse Reactions to Drugs of Special Interest in a Pediatric Oncohematology Service
por: Amaro-Hosey, Kristopher, et al.
Publicado: (2021)

Rare Heterogeneous Adverse Events Associated with mRNA-Based COVID-19 Vaccines: A Systematic Review
por: Oueijan, Rana I., et al.
Publicado: (2022)

mRNA COVID-19 vaccines are well tolerated and myopericarditis is a rare adverse event following immunisation
por: Fenton, Caroline, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2tjpcfgn6kh6betkualn2fe220